Detalhe da pesquisa
1.
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Cell
; 165(2): 317-30, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27058664
2.
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
Proc Natl Acad Sci U S A
; 121(9): e2319492121, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377196
3.
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Nature
; 574(7777): 268-272, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578521
4.
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.
Mol Cell Proteomics
; 17(10): 1892-1908, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29970458
5.
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.
Proc Natl Acad Sci U S A
; 111(1): 255-60, 2014 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24367082
6.
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.
Cell Rep Med
; 5(3): 101471, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38508142
7.
Paradoxical activation of oncogenic signaling as a cancer treatment strategy.
Cancer Discov
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38533987
8.
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.
Cell Rep Med
; 4(2): 100950, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812887
9.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mol Oncol
; 17(6): 964-980, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36650715
10.
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Nat Med
; 29(3): 605-614, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864254
11.
A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer.
Cell Genom
; 2(2): 100100, 2022 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36778660
12.
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Cell Rep Med
; 3(11): 100815, 2022 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36384095
13.
RASON, a new player in cancer's Premier League.
Cell Res
; 33(1): 1-2, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588118
14.
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Nat Med
; 24(7): 961-967, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808006
15.
High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.
Cell Rep
; 21(3): 773-783, 2017 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045843
16.
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
Oncotarget
; 8(24): 38309-38325, 2017 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28415765